VELPHORO Chewable tablet (2022)
Βιβλιογραφική αναφορά
Για την προβολή της πλήρους καταχώρησης απαιτείται συνδρομή σε ισχύ.
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή
Περιεχόμενα
Name of the medicinal product
Velphoro 500 mg chewable tablets.
Qualitative and quantitative composition
Each chewable tablet contains sucroferric oxyhydroxide corresponding to 500 mg iron. The sucroferric oxyhydroxide contained in one tablet is comprised of polynuclear iron (III)-oxyhydroxide (containing ...
Pharmaceutical form
Chewable tablet. Brown, circular tablets embossed with PA500 on one side. Tablets have a 20 mm diameter and a thickness of 6.5 mm.
Therapeutic indications
Velphoro is indicated for the control of serum phosphorus levels in adult chronic kidney disease (CKD) patients on haemodialysis (HD) or peritoneal dialysis (PD). Velphoro is indicated for the control ...
Posology and method of administration
Posology Starting dose for adults and adolescents (≥12 years of age) The recommended starting dose is 1,500 mg iron (3 tablets) per day, divided across the meals of the day. Titration and maintenance for ...
Contraindications
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. Haemochromatosis and any other iron accumulation disorders.
Special warnings and precautions for use
Peritonitis, gastric and hepatic disorders and gastrointestinal surgery Patients with a recent history of peritonitis (within the last 3 months), significant gastric or hepatic disorders and patients with ...
Interaction with other medicinal products and other forms of interaction
Velphoro is almost not absorbed from the gastrointestinal tract. Although the potential for interactions with medicinal products seems low, for concomitant treatment with medicinal products with a narrow ...
Fertility, pregnancy and lactation
Pregnancy There are no available clinical data from the use of sucroferric oxyhydroxide on exposed human pregnancies. Reproductive and developmental toxicity studies in animals revealed no risk with respect ...
Effects on ability to drive and use machines
Velphoro has no or negligible influence on the ability to drive and use machines.
Undesirable effects
Summary of the safety profile The current safety profile of Velphoro is based on a total of 778 patients on haemodialysis and 57 patients on peritoneal dialysis, who received sucroferric oxyhydroxide treatment ...
Overdose
Any instances of overdose of Velphoro (e.g. hypophosphataemia) should be treated by standard clinical practice.
Pharmacodynamic properties
<b>Pharmacotherapeutic group:</b> Drugs for treatment of hyperkalaemia and hyperphosphataemia <b>ATC code:</b> V03AE05 Mechanism of action Velphoro contains sucroferric oxyhydroxide which is comprised ...
Pharmacokinetic properties
Velphoro works by binding phosphate in the gastrointestinal tract and thus the serum concentration is not relevant for its efficacy. Due to the insolubility and degradation characteristics of Velphoro, ...
Preclinical safety data
Nonclinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity and genotoxicity. Effects seen in the rabbit embryo-foetal development ...
List of excipients
Woodberry flavour Neohesperidin-dihydrochalcone Magnesium stearate Colloidal anhydrous silica
Incompatibilities
Not applicable.
Shelf life
3 years. Shelf life after first opening of the bottle: 90 days.
Special precautions for storage
Store in the original package in order to protect from moisture.
Nature and contents of container
High density polyethylene (HDPE) bottle with child-resistant polypropylene closure and foil induction seal, containing a molecular sieve desiccant and cotton. Pack sizes of 30 or 90 chewable tablets. ...
Special precautions for disposal and other handling
Any unused medicinal product or waste material should be disposed of in accordance with local requirements.
Marketing authorization holder
Vifor Fresenius Medical Care Renal Pharma France, 100–101 Terrasse Boieldieu, Tour Franklin La Défense 8, 92042, Paris la Défense Cedex, France
Marketing authorization number(s)
EU/1/14/943/001 EU/1/14/943/002 EU/1/14/943/003 EU/1/14/943/004
Date of first authorization / renewal of the authorization
Date of first authorisation: 26 August 2014 Date of latest renewal: 25 March 2019
Πηγαίο έγγραφο
Το πηγαίο έγγραφο για αυτήν την βιβλιογραφική αναφορά είναι διαθέσιμο προς μεταφόρτωση:
